<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01829841</url>
  </required_header>
  <id_info>
    <org_study_id>FMTN-II-MRCC</org_study_id>
    <nct_id>NCT01829841</nct_id>
  </id_info>
  <brief_title>A Study of Famitinib in Patients With Advanced Metastatic Renal Cell Cancer</brief_title>
  <official_title>A Randomized, Positive-controlled, Double-blind, Multicenter, Phase II Study of Famitinib as First/Second Line Treatment in Patients With Advanced Metastatic Renal Cell Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jiangsu HengRui Medicine Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Cancer Institute and Hospital, Chinese Academy of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Jiangsu HengRui Medicine Co., Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      -  Famitinib is a tyrosin-inhibitor agent targeting at c-Kit, VEGFR2, PDGFR, VEGFR3, Flt1&#xD;
           and Flt3. Phase I study has shown that the toxicity is manageable.&#xD;
&#xD;
        -  The purpose of this study is to compare the efficacy and safety profile between&#xD;
           Famitinib and Sunitinib in patients with metastatic renal cell carcinoma.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2011</start_date>
  <completion_date type="Actual">May 2016</completion_date>
  <primary_completion_date type="Actual">April 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective Response Rate</measure>
    <time_frame>18 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progress free survival (PFS)</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Control Rate (DCR)</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life</measure>
    <time_frame>42-day cycle visit until disease progress</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Adverse Events as a Measure of Safety</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>body vitals, laboratory parameters</measure>
    <time_frame>3 years</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">150</enrollment>
  <condition>Renal Cell Cancer</condition>
  <condition>Metastatic Renal Cell Cancer</condition>
  <arm_group>
    <arm_group_label>Famitinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Famitinib 25 mg qd p.o., 6 weeks per cycle.The treatment continued until disease progression or intolerable toxicity happened or patients withdrawal of consent.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sunitinib</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Sunitinib 50 mg qd p.o., 4 weeks out of 6.The treatment continued until disease progression or intolerable toxicity happened or patients withdrawal of consent.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Famitinib</intervention_name>
    <description>Famitinib 25 mg p.o. qd</description>
    <arm_group_label>Famitinib</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sunitinib</intervention_name>
    <description>Sunitinib 50 mg p.o. qd</description>
    <arm_group_label>Sunitinib</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with histologically confirmed advanced renal cell carcinoma including clear&#xD;
             cell component and not available for surgery&#xD;
&#xD;
          -  First-line therapy or second-line treatment (second-line treatment e.g chemotherapy or&#xD;
             cytokine therapy as first-line treatment failure or resistant patients)&#xD;
&#xD;
          -  With measurable disease (using RECIST1.0 standard conventional CT scan ≥ 20 mm, spiral&#xD;
             CT scan ≥ 10mm, target lesion did not receive radiation therapy, cryotherapy)&#xD;
&#xD;
          -  Male or female, age ≥18 and ≤75&#xD;
&#xD;
          -  ECOG 0-1&#xD;
&#xD;
          -  Life expectancy ≥ 3 months&#xD;
&#xD;
          -  Subjects received surgery, chemotherapy, radiation therapy, cytokines treatment caused&#xD;
             the damage has been restored, the time interval ≥ 4 weeks, and the wound has&#xD;
             completely healed&#xD;
&#xD;
          -  Normal major organ function&#xD;
&#xD;
          -  Signed and dated informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Previously received targeted therapy of the metastatic renal cell carcinoma (such as&#xD;
             sunitinib, Sorafenib)&#xD;
&#xD;
          -  Past or suffering from other cancer, but other than cure basal cell carcinoma and&#xD;
             cervical carcinoma in situ&#xD;
&#xD;
          -  Participated in other clinical trials within four weeks&#xD;
&#xD;
          -  A variety of factors that affect the oral medication (such as inability to swallow,&#xD;
             gastrointestinal resection, chronic diarrhea and intestinal obstruction)&#xD;
&#xD;
          -  Known brain metastases, spinal cord compression, cancer, meningitis, or screening CT&#xD;
             or MRI examination revealed brain or leptomeningeal disease&#xD;
&#xD;
          -  Patients with hypertension (systolic blood pressure&gt; 140 mmHg, diastolic blood&#xD;
             pressure&gt; 90 mmHg). Patients with more than Class I, myocardial ischemia or myocardial&#xD;
             infarction, arrhythmia (including QT interval ≥ 440ms) and class I heart failure.&#xD;
&#xD;
          -  Urine protein ≥ + + and confirmed the 24-hour urinary protein&gt;1.0 g&#xD;
&#xD;
          -  Coagulopathy with bleeding tendency (such as active peptic ulcer) or are receiving&#xD;
             thrombolytic or anticoagulant therapy&#xD;
&#xD;
          -  Previous hyperactivity / venous thromboembolic events, such as cerebrovascular&#xD;
             accident (including transient ischemic attacks), deep vein thrombosis and pulmonary&#xD;
             embolism&#xD;
&#xD;
          -  The preexisting abnormal thyroid function, even in the case of medication still can&#xD;
             not be maintained within the normal range&#xD;
&#xD;
          -  With a history of abuse of psychotropic drugs or mental disorders&#xD;
&#xD;
          -  Patients with Hepatitis B or Hepatitis C&#xD;
&#xD;
          -  History of immunodeficiency, including HIV testing positive or suffering from&#xD;
             acquired, congenital immunodeficiency disease, or a history of organ transplantation&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jinwan Wang, M.D</last_name>
    <role>Study Chair</role>
    <affiliation>Cancer Institute and Hospital, Chinese Academy of Medical Sciences</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jianhui Ma, M.D</last_name>
    <role>Study Chair</role>
    <affiliation>Cancer Institute and Hospital, Chinese Academy of Medical Sciences</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cancer Institute and Hospital Chinese Academy of Medical Sciences</name>
      <address>
        <city>Beijing</city>
        <zip>100021</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>April 2013</verification_date>
  <study_first_submitted>April 8, 2013</study_first_submitted>
  <study_first_submitted_qc>April 8, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 11, 2013</study_first_posted>
  <last_update_submitted>May 1, 2018</last_update_submitted>
  <last_update_submitted_qc>May 1, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 3, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>MRCC</keyword>
  <keyword>Metastatic Renal Cell Cancer</keyword>
  <keyword>Famitinib</keyword>
  <keyword>Sunitinib</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Renal Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sunitinib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

